US equities |
NVDA $237.13 ▲+1.36% SPCX $165.30 ▲+3.99% MU $1,063.10 ▼-1.10% TSLA $378.36 ▲+2.10% MSFT $526.33 ▲+1.70% INTC $116.42 ▼-2.43% SNDK $1,720.08 ▲+0.01% AMD $628.05 ▼-0.92%
FinancialContent

Obsidian Therapeutics, Inc. - Common Stock (NQ:OBX)

13.40 -0.19 (-1.40%)
Delayed Quote Updated: 10:04 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Obsidian Therapeutics, Inc. - Common Stock

News headline image
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
From Obsidian Therapeutics, Inc.
Via Business Wire
News headline image
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
From Obsidian Therapeutics, Inc.
Via Business Wire